Nantes, France – April 30th, 2024 - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS Society’s commercial research initiative Fast Forward to advance IFB-...